Experimental drug rigosertib tested against aggressive skin cancer in rare disease patients
Disease control
Completed
This small early-phase trial tested an experimental drug called rigosertib in just 2 people with a rare blistering skin disease (recessive dystrophic epidermolysis bullosa) who also had advanced skin cancer. The goal was to see if the drug could shrink tumors and whether it was s…
Phase: PHASE1, PHASE2 • Sponsor: Prof. Johann Bauer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC